Abstract:
This study explores the role of tier-3 biopharmaceutical antibiotics in the prognosis and dual treatment of bacterial and viral infections. Through a five-year clinical observation, improper antibiotic prescriptions were linked to exac erbated pulmonary conditions. A novel treatment protocol incorporating antibiotics, antivirals, and immunotherapy demonstrated efficacy in reversing chronic bronchial disorders. The research underscores the importance of precise pharmaceutical interventions and regulatory oversight in managing infectious diseases.